Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastroenterology | 7 | 2024 | 157 | 1.330 |
Why?
|
| Liver Transplantation | 5 | 2024 | 1201 | 0.530 |
Why?
|
| Colonoscopy | 3 | 2014 | 304 | 0.440 |
Why?
|
| Liver Cirrhosis | 3 | 2016 | 276 | 0.420 |
Why?
|
| Colonoscopes | 2 | 2011 | 13 | 0.420 |
Why?
|
| Adenoma | 2 | 2011 | 260 | 0.350 |
Why?
|
| Hepatic Encephalopathy | 2 | 2023 | 38 | 0.300 |
Why?
|
| Colonic Neoplasms | 2 | 2011 | 587 | 0.300 |
Why?
|
| Rifamycins | 1 | 2016 | 7 | 0.250 |
Why?
|
| Fellowships and Scholarships | 2 | 2021 | 147 | 0.250 |
Why?
|
| Hepatorenal Syndrome | 1 | 2016 | 9 | 0.250 |
Why?
|
| Education, Medical, Graduate | 3 | 2024 | 438 | 0.250 |
Why?
|
| Esophageal Fistula | 1 | 2006 | 12 | 0.250 |
Why?
|
| Pericardial Effusion | 1 | 2006 | 24 | 0.240 |
Why?
|
| Cardiac Tamponade | 1 | 2006 | 23 | 0.240 |
Why?
|
| Liver Diseases | 3 | 2021 | 249 | 0.240 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 96 | 0.230 |
Why?
|
| Hepatitis C | 2 | 2021 | 184 | 0.220 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2021 | 647 | 0.210 |
Why?
|
| Lactulose | 1 | 2023 | 22 | 0.200 |
Why?
|
| Esophageal Neoplasms | 1 | 2006 | 345 | 0.200 |
Why?
|
| Antiviral Agents | 2 | 2021 | 504 | 0.200 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 341 | 0.180 |
Why?
|
| Curriculum | 3 | 2021 | 616 | 0.180 |
Why?
|
| Internship and Residency | 3 | 2021 | 1134 | 0.170 |
Why?
|
| Viremia | 1 | 2021 | 53 | 0.170 |
Why?
|
| Gastroenterologists | 1 | 2021 | 31 | 0.170 |
Why?
|
| United States | 8 | 2024 | 7785 | 0.170 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2020 | 18 | 0.160 |
Why?
|
| Donor Selection | 1 | 2021 | 81 | 0.160 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2020 | 24 | 0.160 |
Why?
|
| Internal Medicine | 2 | 2021 | 371 | 0.160 |
Why?
|
| Clinical Competence | 4 | 2021 | 858 | 0.150 |
Why?
|
| Faculty, Medical | 1 | 2021 | 207 | 0.150 |
Why?
|
| Middle Aged | 12 | 2021 | 28299 | 0.140 |
Why?
|
| Inappropriate Prescribing | 1 | 2017 | 21 | 0.130 |
Why?
|
| Tissue Donors | 1 | 2021 | 542 | 0.130 |
Why?
|
| Proton Pump Inhibitors | 1 | 2017 | 34 | 0.130 |
Why?
|
| Male | 15 | 2021 | 45792 | 0.130 |
Why?
|
| Humans | 22 | 2024 | 95992 | 0.130 |
Why?
|
| Paracentesis | 1 | 2016 | 10 | 0.120 |
Why?
|
| Ascites | 1 | 2016 | 56 | 0.120 |
Why?
|
| Students, Medical | 1 | 2021 | 455 | 0.120 |
Why?
|
| Multidetector Computed Tomography | 1 | 2016 | 61 | 0.120 |
Why?
|
| Adult | 11 | 2021 | 28636 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 492 | 0.120 |
Why?
|
| Deficiency Diseases | 1 | 2015 | 12 | 0.110 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2017 | 246 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2016 | 426 | 0.110 |
Why?
|
| Liver Failure | 1 | 2015 | 69 | 0.110 |
Why?
|
| Education, Medical | 1 | 2017 | 252 | 0.110 |
Why?
|
| Zinc | 1 | 2015 | 101 | 0.110 |
Why?
|
| Esophagitis | 1 | 2014 | 40 | 0.110 |
Why?
|
| Phenylbutyrates | 1 | 2014 | 9 | 0.110 |
Why?
|
| Female | 13 | 2021 | 49980 | 0.100 |
Why?
|
| Ammonia | 1 | 2014 | 45 | 0.100 |
Why?
|
| Hyperammonemia | 1 | 2014 | 14 | 0.100 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2014 | 99 | 0.100 |
Why?
|
| Glycerol | 1 | 2014 | 37 | 0.100 |
Why?
|
| Radiographic Image Enhancement | 1 | 2016 | 467 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2014 | 159 | 0.100 |
Why?
|
| Sirolimus | 1 | 2014 | 177 | 0.100 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 472 | 0.100 |
Why?
|
| Hospitalization | 2 | 2016 | 946 | 0.100 |
Why?
|
| Liver Neoplasms | 2 | 2016 | 790 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 197 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2014 | 239 | 0.090 |
Why?
|
| Young Adult | 3 | 2020 | 7034 | 0.090 |
Why?
|
| Hospitalists | 1 | 2014 | 143 | 0.090 |
Why?
|
| Fatal Outcome | 2 | 2014 | 303 | 0.080 |
Why?
|
| Quality of Health Care | 1 | 2014 | 403 | 0.080 |
Why?
|
| Ribavirin | 1 | 2010 | 40 | 0.080 |
Why?
|
| Interferon-alpha | 1 | 2010 | 194 | 0.080 |
Why?
|
| Adolescent | 2 | 2020 | 9878 | 0.080 |
Why?
|
| Hepacivirus | 1 | 2010 | 137 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2016 | 721 | 0.070 |
Why?
|
| Aged | 8 | 2016 | 20927 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2010 | 376 | 0.070 |
Why?
|
| Time Factors | 4 | 2021 | 5593 | 0.070 |
Why?
|
| Career Choice | 2 | 2021 | 164 | 0.070 |
Why?
|
| Graft Survival | 2 | 2021 | 942 | 0.060 |
Why?
|
| Midodrine | 1 | 2016 | 5 | 0.060 |
Why?
|
| Vasoconstrictor Agents | 1 | 2016 | 68 | 0.060 |
Why?
|
| Viral Load | 2 | 2021 | 164 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2016 | 10307 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2021 | 311 | 0.060 |
Why?
|
| End Stage Liver Disease | 1 | 2016 | 73 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2021 | 9228 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2021 | 1014 | 0.050 |
Why?
|
| Hospital Costs | 2 | 2016 | 117 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 905 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 7224 | 0.050 |
Why?
|
| Risk Factors | 3 | 2021 | 5992 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 1618 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2016 | 983 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1962 | 0.040 |
Why?
|
| Incidence | 1 | 2016 | 1723 | 0.040 |
Why?
|
| Program Development | 1 | 2021 | 136 | 0.040 |
Why?
|
| Educational Status | 1 | 2021 | 202 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2021 | 2498 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1982 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1018 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 1087 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 372 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2021 | 246 | 0.040 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2016 | 590 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 848 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 420 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 708 | 0.030 |
Why?
|
| Income | 1 | 2016 | 90 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 71 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 3922 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 255 | 0.030 |
Why?
|
| Forecasting | 1 | 2016 | 317 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 155 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 626 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 311 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 138 | 0.030 |
Why?
|
| Urea | 1 | 2014 | 59 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 438 | 0.030 |
Why?
|
| Glutamine | 1 | 2014 | 99 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 500 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2016 | 485 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2017 | 502 | 0.020 |
Why?
|
| Urban Population | 1 | 2014 | 240 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 890 | 0.020 |
Why?
|
| Length of Stay | 1 | 2016 | 835 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2014 | 245 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 2042 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 1017 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 422 | 0.020 |
Why?
|
| Inpatients | 1 | 2014 | 348 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 1978 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2014 | 401 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1130 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 1561 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2014 | 645 | 0.020 |
Why?
|
| Physicians | 1 | 2017 | 707 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2010 | 88 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 297 | 0.020 |
Why?
|
| Disposable Equipment | 1 | 2010 | 23 | 0.020 |
Why?
|
| Mass Screening | 1 | 2015 | 710 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1792 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2885 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 12525 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 484 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1959 | 0.020 |
Why?
|
| Chicago | 1 | 2014 | 1505 | 0.020 |
Why?
|
| Colonic Polyps | 1 | 2010 | 137 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 435 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 1006 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 789 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 930 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 3115 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 1273 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 1096 | 0.020 |
Why?
|
| Genotype | 1 | 2010 | 1883 | 0.010 |
Why?
|
| Animals | 1 | 2023 | 28901 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2010 | 4690 | 0.010 |
Why?
|